Akebia Therapeutics

Dialysis population and ESA utilization are structurally stable, and Vafseo adoption is proceeding via protocols across U.S. dialysis organizations, which supports recurring revenue.

However, the 2027 price step‑down injects non‑trivial discontinuity to top‑line and gross margin trajectories, and Auryxia revenue is declining due to generic competition. Regulatory or safety updates could alter adoption, though post‑hoc and interim data are supportive.

Overall predictability is moderate: volumes are steady, but economics are policy‑driven and step‑wise.